An AI-enabled digital pathology software provider, Crosscope Inc., and Waleed Pharmacy & Stores LLC, part of the Omar Zawawi Establishment (OMZEST) group, have signed an MOU to facilitate next-generation transformation in the Histopathology Landscape using Crosscope’s AI-enabled digital pathology platform. They will bring state-of-the-art technical solutions to Oman so that they can commercialize comprehensive cancer care, thereby reducing Oman’s cancer burden.

“We are delighted to join forces with the Waleed Pharmacy group. Waleed Pharmacy’s experienced team has a proven track record of delivering and deploying healthcare IT solutions in the Oman region and represents a perfect partner for Crosscope. By teaming up, we are confident that we have created the synergies to boost the development and commercialization of our digital pathology workflows,” said Dr. Jayendra Shinde, CEO of Crosscope.

Waleed Pharmacy will be Crosscope’s official representative in Oman as a result of this partnership. Both firms plan to provide cancer diagnosis service providers with state-of-the-art comprehensive Digital Pathology Platforms, AI, and ML capabilities. They’ll also look into all available options for collaboration, collaborating, and using each other’s knowledge, network, and know-how to improve the region’s cancer diagnostics environment.

“We are exuberant with our recent collaboration with Crosscope. We are confident that as a joint force we will bring best in class Health IT solutions around the world to the GCC countries beginning & concentrating primarily in Oman,” says Pawan Mordani, General Manager for Waleed Pharmacy. Further, he added, “This partnership will strengthen our efforts to not only reduce the cancer disease burden but also improve the overall health structure in Oman which will help in better patient outcomes.”

Crosscope also plans to collaborate with the region’s top key opinion leaders in prestigious hospitals, clinical institutions, diagnostic chains, R&D labs, research organizations, pharmaceutical companies, and other organizations in the related space where the company’s products add clinical value to users.